Therapeutic Solutions International Inc. (OTCMKTS:TSOI) is moving in range after the company announced preclinical data showing JadiCell Universal Donor stem cell’s efficacy in reversing and inhibiting neuroinflammation caused brain damage in animal models representing post-COVID infection. In addition, after several experiments, the company established clinically relevant JadiCell doses that can suppress astrogliosis, which is a sign of induced brain damage and reversing cognitive and memory deficits evaluated by Morris Water Maze and the Modified Barnes Maze test.
The studies are part of the ongoing work in JadiCell development as a potential post-COVID brain damage treatment.
The company’s subsidiary Campbell Neurosciences announced data showing that tolerogenic dendritic cells administration in schizophrenia animal models led to multiple neurological manifestations suppression. The focus was the relationship between therapeutic activity and increased T regulatory cells. The company had previously reported that T regulatory cells administration could suppress schizophrenia.
The company is looking forward to starting human clinical studies. In the coming months, TSOI is a stock to watch.
On Wednesday, TSOI stock jumped 1% to $0.0415 with more than 5.28 million shares, compared to its average volume of 6.46 million shares. The stock has moved within a range of $0.0400 – 0.0440 after opening the trade at $0.0408. Over the past 52-week, the stock has been trading within a range of $0.0029 – 0.1729.